UNITY Biotechnology Extends Phase 2b ASPIRE Clinical Study for UBX1325 in DME, Aiming to Enhance Durability and Statistical Power
SOUTH SAN FRANCISCO, Calif. April 23, 2024 - UNITY Biotechnology, Inc. (UNITY) NASDAQ: UBX, a prominent biotechnology company focused on developing innovative therapies to slow down, halt or even reverse diseases associated with aging, disclosed today the extension of its ongoing Phase 2b ASPIRE study of UBX1325. This extension will allow for an additional 12 weeks, totaling 36 weeks, to assess the potential for greater durability when compared to aflibercept. Simultaneously, the study has been upsized from 40 to 50 patients to bolster its statistical power. The primary of the ASPIRE study is to investigate the safety, efficacy, and long-term durability of UBX1325 as a monotherapy in comparison to aflibercept in individuals diagnosed with diabetic macular edema (DME).
Promisingly, Unity Biotechnology has also previously announced the successful dosing of the first patients in the Phase 2 ASPIRE study of UBX1325, further emphasizing the company’s dedication to advancing the field of biotechnology. As a result, topline 16-week data from this study are highly anticipated and expected to be released in the fourth quarter of 2024.
Diabetic macular edema is a condition that affects diabetic individuals, causing swelling and fluid leakage in the macula, which is a crucial part of the retina responsible for sharp, central vision. This impairment can significantly impact a person’s quality of life and independence, making it essential for researchers and scientists to explore novel therapeutic approaches.
UNITY Biotechnology is at the forefront of targeting aging-related diseases by developing groundbreaking treatments that have the potential to transform the lives of millions of people. UBX1325, the focal point of the ASPIRE study, represents a new class of drugs known as senolytics. Senescent cells are those that have lost their ability to divide but remain active and can secrete harmful substances that contribute to age-related diseases. UBX1325 eradicates these senescent cells, aiming to halt or reverse the progression of diabetic macular edema.
The decision to extend the ASPIRE study from 24 to 36 weeks demonstrates UNITY Biotechnology’s determination to thoroughly evaluate UBX1325’s durability in combating DME. By conducting a head-to-head comparison with aflibercept, a proven treatment for DME, the study will provide clear insights into UBX1325’s potential as an innovative therapeutic option that offers long-term benefits.
Furthermore, the decision to increase the patient size from 40 to 50 individuals signifies UNITY Biotechnology’s commitment to enhancing the statistical power of the study. This change will enable more robust and comprehensive data analysis, ultimately reinforcing the validity and reliability of the study findings. By combining an extended study duration with a larger patient cohort, UNITY Biotechnology is positioning itself to generate compelling evidence supporting the potential of UBX1325 in treating DME.
Given UNITY Biotechnology’s extensive track record of innovation and dedication to revolutionizing the field of biotechnology, the announcement of the ASPIRE study extension serves as another milestone in their mission to address age-related diseases. The anticipation surrounding the release of topline 16-week data later this year reaffirms the industry’s eagerness to witness the potential therapeutic breakthroughs brought forth by UNITY Biotechnology.
In conclusion, UNITY Biotechnology’s decision to extend the Phase 2b ASPIRE study for UBX1325 in DME represents a significant milestone in the research and development of novel treatments for aging-related diseases. This decision demonstrates unity’s commitment to thoroughly evaluating UBX1325’s durability and efficacy compared to existing treatment options. With the topline 16-week data expected to be unveiled later this year, the anticipation is building, and the results have the potential to revolutionize the treatment landscape for individuals affected by diabetic macular edema.
Comments